21 CFR § 312.50 Investigational New Drug Application

§ 312.50 General responsibilities of sponsors.

Current through Sep 8, 2026 · Read all of Part 312

⚠ 4 pending changes to Part 312

Sponsors are responsible for selecting qualified investigators, providing them with the information they need to conduct an investigation properly, ensuring proper monitoring of the investigation(s), ensuring that the investigation(s) is conducted in accordance with the general investigational plan and protocols contained in the IND, maintaining an effective IND with respect to the investigations, and ensuring that FDA and all participating investigators are promptly informed of significant new adverse effects or risks with respect to the drug. Additional specific responsibilities of sponsors are described elsewhere in this part.

← § 312.48 Dispute resolution.§ 312.52 Transfer of obligations to a contract research organization. →